Cohlhepp Ryan sold $833K of BCAX
Cohlhepp Ryan (President and COO) sold 28,750 shares of Bicara Therapeutics Inc. (BCAX) at an average of $28.98 ($28.76–$30.35, $0.83M total) across 4 trades over 2026-07-08 to 2026-07-09 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
An officer/director sold 28,750 shares for about $833k at prices ranging from $28.7589 to $30.3549, with holdings after the sale of 181,641 shares.
Market read
Traders may monitor for follow-on insider activity, but this specific disclosure is unlikely to change valuation absent other company catalysts.
What to watch
The article does not provide context on total insider holdings changes over time, nor any concurrent company-specific catalysts (earnings, trial updates, financing).
Background
The article is an SEC Form 4 insider transaction disclosure for Bicara Therapeutics Inc.
Ticker impact
Bicara Therapeutics insider Cohlhepp Ryan (President and COO) sold $833,129 of BCAX shares via a 10b5-1 plan across four trades in July 8-9.
Near-term price impact is likely limited; any effect would be sentiment-driven rather than fundamental.
The filing is a Form 4 insider sale, not a buy, and it explicitly states a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.
Market effects
No clear sector read-through from a single insider sale at a biotech issuer.
None.
None.
Counterpoint
The sale could be purely liquidity-driven under the 10b5-1 plan and may not reflect negative expectations.
Key entities
- issuerBicara Therapeutics Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderCohlhepp Ryan
President and COO who executed the open-market sale under a 10b5-1 plan.
